Related Experiment Videos
Transmitter dysfunction during the process of schizophrenia
1Department of Psychiatry, University Hospital Bispebjerg, Copenhagen, Denmark.
Acta Psychiatrica Scandinavica. Supplementum
|May 4, 1999
Summary
This review examines neurotransmitter systems involved in schizophrenia, focusing on dopamine, serotonin, and glutamate. Novel antipsychotics may offer improved treatment by modulating sensorimotor gating.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Schizophrenia pathogenesis involves multiple neurotransmitter systems.
- Atypical antipsychotics and clozapine target dopaminergic, serotonergic, and glutamatergic systems.
- Understanding transmitter dysfunction is key to addressing perceptual and adaptive deficits in schizophrenia.
Purpose of the Study:
- To review neurotransmitter systems implicated in schizophrenia.
- To explore the mode of action of atypical antipsychotics and clozapine.
- To propose a hypothesis for schizophrenia pathogenesis involving cortical defects and transmitter dysfunction.
Main Methods:
- Literature review focusing on dopaminergic, serotonergic, and glutamatergic systems.
- Discussion of transmitter dysfunction's impact on perception and adaptation.
- Hypothetical modeling of schizophrenia pathogenesis and treatment strategies.
Main Results:
- A hypothesis is proposed where primary cortical defects lead to secondary transmitter dysfunction and dopaminergic sensitization.
- Flexible modulation of sensorimotor gating is suggested as a therapeutic strategy.
- Atypical antipsychotics' broader receptor profiles may explain reduced extrapyramidal side-effects and improved cognitive/negative symptoms.
Conclusions:
- Neurotransmitter systems, particularly dopamine, serotonin, and glutamate, are central to schizophrenia.
- Atypical antipsychotics offer a promising avenue for treatment through nuanced modulation of these systems.
- Targeting sensorimotor gating represents a potential strategy for managing schizophrenia symptoms.